Drug Profile


Alternative Names: TC-0569; TC-5619; TC-5619-238

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Targacept
  • Class Amides; Azabicyclo compounds; Benzofurans; Nootropics; Pyridines; Quinuclidines; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders

Most Recent Events

  • 02 Aug 2016 Catalyst Biosciences enters into a definitive agreement with Attenua for the divestiture of its neuronal nicotinic receptors
  • 20 Aug 2015 Targacept has merged into Catalyst Biosciences and changed its name to Catalyst Biosciences
  • 16 Dec 2013 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top